Zhe Jiang Dayang Biotech Group Past Earnings Performance
Past criteria checks 4/6
Zhe Jiang Dayang Biotech Group's earnings have been declining at an average annual rate of -1.2%, while the Chemicals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 14.2% per year. Zhe Jiang Dayang Biotech Group's return on equity is 7.1%, and it has net margins of 6.8%.
Key information
-1.2%
Earnings growth rate
-9.4%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 14.2% |
| Return on equity | 7.1% |
| Net Margin | 6.8% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Zhe Jiang Dayang Biotech Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1,038 | 71 | 81 | 39 |
| 31 Mar 23 | 1,115 | 92 | 70 | 36 |
| 31 Dec 22 | 1,058 | 81 | 68 | 34 |
| 30 Sep 22 | 951 | 51 | 67 | 36 |
| 30 Jun 22 | 890 | 55 | 66 | 39 |
| 31 Mar 22 | 801 | 53 | 64 | 30 |
| 31 Dec 21 | 783 | 70 | 64 | 28 |
| 30 Sep 21 | 750 | 84 | 60 | 25 |
| 30 Jun 21 | 742 | 92 | 61 | 22 |
| 31 Mar 21 | 719 | 96 | 56 | 22 |
| 31 Dec 20 | 678 | 92 | 54 | 22 |
| 30 Sep 20 | 664 | 101 | 49 | 21 |
| 30 Jun 20 | 629 | 92 | 51 | 21 |
| 31 Mar 20 | 600 | 81 | 56 | 19 |
| 31 Dec 19 | 622 | 79 | 59 | 20 |
| 30 Sep 19 | 598 | 73 | 61 | 18 |
| 30 Jun 19 | 605 | 72 | 59 | 16 |
| 31 Mar 19 | 590 | 72 | 53 | 23 |
| 01 Jan 19 | 584 | 71 | 59 | 18 |
| 01 Oct 18 | 599 | 68 | 67 | 13 |
| 30 Jun 18 | 613 | 66 | 75 | 8 |
| 31 Mar 18 | 590 | 58 | 80 | 0 |
| 31 Dec 17 | 555 | 50 | 76 | 0 |
| 30 Sep 17 | 500 | 44 | 64 | 12 |
| 30 Jun 17 | 445 | 37 | 76 | 5 |
| 31 Mar 17 | 441 | 33 | 80 | 0 |
| 01 Jan 17 | 441 | 29 | 75 | 0 |
| 30 Sep 16 | 454 | 30 | 72 | 0 |
| 30 Jun 16 | 466 | 32 | 69 | 0 |
| 31 Mar 16 | 457 | 28 | 70 | 0 |
| 01 Jan 16 | 448 | 24 | 72 | 0 |
| 01 Jan 15 | 459 | 28 | 72 | 0 |
| 31 Dec 13 | 500 | 26 | 68 | 0 |
Quality Earnings: 003017 has high quality earnings.
Growing Profit Margin: 003017's current net profit margins (6.8%) are higher than last year (5.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 003017's earnings have declined by 1.2% per year over the past 5 years.
Accelerating Growth: 003017's earnings growth over the past year (39.9%) exceeds its 5-year average (-1.2% per year).
Earnings vs Industry: 003017 earnings growth over the past year (39.9%) exceeded the Chemicals industry -19.5%.
Return on Equity
High ROE: 003017's Return on Equity (7.1%) is considered low.